['hiv-1']
['doravirine', 'darunavir', 'ritonavir', 'truvada™ or epzicom™/kivexa™']

        Inclusion Criteria:

          -  Is HIV-1 positive and has HIV treatment indicated based on physician assessment.

          -  Has received no (0 days of) antiretroviral therapy (ART), including investigational
             antiretroviral agents.

          -  Is considered clinically stable with no signs or symptoms of active infection for at
             least 2 weeks prior to the start of treatment.

          -  Female is highly unlikely to become pregnant, or male is highly unlikely to impregnate
             a partner because they are not of reproductive potential, or agree to practice
             abstinence or use acceptable contraception for up to 14 days after the last dose of
             study drug.

          -  Eligibility for the Study Extension 1 at the Week 96 visit: 1) completed the Week 96
             visit, 2) derived benefit from participation through Week 96 in the opinion of the
             investigator, 3) is a clinically-appropriate candidate for an additional 96 weeks of
             treatment with the Study Extension regimen.

          -  Eligibility for the Study Extension 2 at the Week 192 visit: 1) completed the Week 192
             visit, 2) derived benefit from participation through Week 192 in the opinion of the
             investigator, 3) is a clinically-appropriate candidate for 96 weeks of treatment with
             the Study Extension regimen.

        Exclusion Criteria:

          -  Uses or has had a recent history of using recreational or illicit drugs.

          -  Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an
             agent that is active against HIV-1.

          -  Has documented or known resistance to study drugs including doravirine, darunavir,
             ritonavir, emtricitabine, tenofovir, abacavir and/or lamivudine.

          -  Has participated in a study with an investigational compound/device within the prior
             month, or anticipates doing so during this study.

          -  Has used systemic immunosuppressive therapy or immune modulators within the prior 30
             days, or anticipates doing so during this study.

          -  Has significant hypersensitivity or other contraindication to any of the components of
             the study drugs.

          -  Has a current (active) diagnosis of acute hepatitis due to any cause.

          -  Is pregnant, breastfeeding or expecting to conceive at any time during the study.

          -  Female who expects to donate eggs, or male who expects to donate sperm at any time
             during the study.
      